Osteopore (OSX.AX) Stock Price

Osteopore Ltd. develops and markets bioresorbable polymer implants for neurosurgical, orthopaedic, and maxillofacial surgeries. The company commercializes bespoke products engineered to facilitate bone healing, utilizing patented technology that fabricates micro-structured scaffolds through 3D printing and bioresorbable materials. Key products include Osteoplug in plug and strip configurations for craniotomy gap filling, Osteomesh, and Osteoplug-C for craniofacial applications. These solutions support bone tissue integration from the skull to the bone flap, targeting procedures such as cranioplasty, craniosynostosis, and guided bone regeneration. The company serves medical professionals and healthcare facilities requiring advanced bone regeneration solutions. Its products are designed for specific surgical applications including craniotomy, orbital floor reconstruction, socket preservation, and minimally invasive skull base surgery. Osteopore Ltd. focuses on delivering patient-specific implants (PSI) for cranial and mandibular procedures, alongside solutions for burr hole restoration with shunt drainage systems. These offerings cater to specialized surgical segments demanding precision and biocompatibility. Osteopore Ltd.'s revenue streams derive from the sale of its proprietary implant systems to hospitals and surgical centers. The company’s technology enables the production of custom implants that address complex bone healing needs, particularly in neurosurgery, orthopaedics, and maxillofacial procedures. By providing tailored solutions for cranioplasty, craniosynostosis, and guided bone regeneration, the company meets the demands of healthcare providers seeking effective bone regeneration technologies.